Skip to main content
SpringerLink
Log in

Oxaliplatin activity in head and neck cancer cell lines

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N′] [oxalato(2-)-O,O′] platinum; Eloxatin) is a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) carrier ligand, which has a wide spectrum of anticancer activity in vitro systems and has displayed preclinical and clinical activity in a wide variety of tumors. To investigate its in vitro activity against head and neck cancer, we exposed two head and neck cancer cell lines to the compound, created a variant resistant to cisplatin to study cross-resistance to the compound and analyzed the potential radiosensitizing effect of the drug. We report here that oxaliplatin was cytotoxic at similar doses to cisplatin in these cells. There was no cross-resistance to cisplatin, as demonstrated by different IC50 values in these cell lines and the sensitivity to oxaliplatin of the cisplatin-resistant cell line. There was an effective radiosensitizer effect of the compound in either cell line. Additional in vitro and in vivo experimentation is warranted in order to support the use of oxaliplatin as a radiosensitizer in head and neck cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E (2000) Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35:75–93

    Article  CAS  PubMed  Google Scholar 

  2. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218

    CAS  PubMed  Google Scholar 

  3. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920–927

    CAS  PubMed  Google Scholar 

  4. Cassidy J (2000) Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract 54:399–402

    CAS  PubMed  Google Scholar 

  5. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8:876–885

    CAS  PubMed  Google Scholar 

  6. Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, Brienza S (1996) Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 32B:278–279

    CAS  PubMed  Google Scholar 

  7. Bandala E, Espinosa M, Maldonado V, Melendez-Zajgla J (2001) Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. Biochem Pharmacol 62:13–19

    Article  CAS  PubMed  Google Scholar 

  8. Hernandez P, Olivera P, Duenas-Gonzalez A, Perez-Pastenes MA, Zarate A, Maldonado V, Melendez-Zajgla J (2001) Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol 48:488–492

    Article  CAS  PubMed  Google Scholar 

  9. Fertil B, Dertinger H, Courdi A, Malaise EP (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99:73–84

    CAS  PubMed  Google Scholar 

  10. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841–1845

    CAS  PubMed  Google Scholar 

  11. Royce ME, Hoff PM, Padzur R (1999) Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexed. Curr Oncol Rep 1:161–167

    CAS  PubMed  Google Scholar 

  12. Soulie P, Raymond E, Brienza S, Cvitkovic E (1997) Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer 84:665–673

    CAS  PubMed  Google Scholar 

  13. Mukai M, Kanzaki A, Chen ZS, Miyashita H, Sumizawa T, Furukawa T, Haraguchi M, Takebayashi Y, Takamatsu H, Akiyama S (2002) Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. Oncol Rep 9:839–844

    CAS  PubMed  Google Scholar 

  14. Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, Kuwano M, Akiyama S (1994) Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85:426–433

    CAS  PubMed  Google Scholar 

  15. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3:1151–1157

    CAS  PubMed  Google Scholar 

  16. Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R (1999) Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 35:86–90

    Article  CAS  PubMed  Google Scholar 

  17. Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968–3971

    CAS  PubMed  Google Scholar 

  18. Scheeff ED, Briggs JM, Howell SB (1999) Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56:633–643

    CAS  PubMed  Google Scholar 

  19. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79:1104–1110

    Article  CAS  PubMed  Google Scholar 

  20. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104

    Article  PubMed  Google Scholar 

  21. Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119–1124

    Article  PubMed  Google Scholar 

  22. Gergel TJ, Leichman L, Nava HR, Blumenson LE, Loewen GM, Gibbs JE, Khushalani NI, Leichman CG, Bodnar LM, Douglass HO, Smith JL, Kuettel MR, Proulx GM (2002) Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. Cancer J 8:451–460

    PubMed  Google Scholar 

  23. Magne N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcie S, Lagrange JL, Milano G (2003) Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 64:280–287

    Article  CAS  PubMed  Google Scholar 

  24. O’Neill BH (2003) Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. Semin Radiat Oncol 13:441–453

    PubMed  Google Scholar 

Download references

Acknowledgements

We want to thank Ms Gisela Olvera for her kind help. This work was partly supported by grants 42039-A1 (to V. Maldonado) and 42040-A1 (to J. Meléndez-Zajgla) from Consejo Nacional de Ciencia y Tecnología, México.

Author information

Authors and Affiliations

  1. Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Av. San Fernando # 22. Tlalpan, 14000, Mexico, DF, Mexico

    Magali Espinosa, Moises Martinez, Jaime G. De la Garza, Vilma Maldonado & Jorge Meléndez-Zajgla

  2. Departamento de Educación Médica Continua, Mexico, DF, Mexico

    José Luis Aguilar

  3. Departamento de Radiología, Mexico, DF, Mexico

    Aída Mota

Authors
  1. Magali Espinosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moises Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Luis Aguilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aída Mota
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jaime G. De la Garza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vilma Maldonado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jorge Meléndez-Zajgla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge Meléndez-Zajgla.

Additional information

Magali Espinosa and Moises Martinez contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Espinosa, M., Martinez, M., Aguilar, J.L. et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol 55, 301–305 (2005). https://doi.org/10.1007/s00280-004-0847-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0847-5

Keywords

Search

Navigation